ters in the acute phase to determine whether clinically relevant changes occur. We also aimed to conduct a comparative literature review of other papers reporting post-AMI lipid levels.
Materials and Methods
The SPACE ROCKET trial was an open-label, national, multicenter, randomized, controlled trial with blinded end points comparing the efficacy and tolerability of 40 mg simvastatin versus 10 mg rosuvastatin (4 ) . Detailed inclusion and exclusion criteria are reported with the main trial (4 ) . Briefly, the target population was hospital inpatients admitted with an acute coronary event within the preceding 2 weeks, requiring secondary prevention with a statin in the opinion of the attending clinician. All patients admitted to participating hospitals with increased cardiac markers (serum creatinine kinase more than two times the upper limit of normal or troponin I/T greater than the value representing 10% analytical CV) were screened, and eligibility was established by SPACE ROCKET clinical research nurses.
CONCOMITANT MEDICATIONS
Patients were not excluded if they were already taking a statin at time of admission unless it was 80 mg simvastatin or 80 mg atorvastatin per day. Patients were excluded if they were taking medication associated with an increased risk of rhabdomyolysis in combination with statins (e.g., strong cytochrome P450 -3A4 inhibitors such as macrolide antibiotics) or other concomitant drugs with special warnings or precautions, including fibric acid derivatives, cyclosporine, nicotinic acid, azole antifungals, protease inhibitors, amiodarone, verapamil, or nefazodone.
LIPID ASSESSMENT
The SPACE ROCKET clinical research nurses recorded results of routine hospital admission (day 1) blood samples (fasting or nonfasting) where available. The SPACE ROCKET clinical research nurses also took a prerandomization blood sample for central laboratory analysis, typically on days 2-4 of their inpatient stay after acute admission (fasting).
In the central laboratory, serum concentrations of total cholesterol, HDL cholesterol, and triglycerides were measured with enzymatic reagents on Siemens Advia to the manufacturer's protocols (Siemens Healthcare Diagnostics). LDL cholesterol was calculated using the Friedewald equation (5 ), where triglycerides were Ͻ4.5 mmol/L. The routine day 1 samples were analyzed locally (at admitting hospitals) using a range of protocols, and these were recorded. Participants recruited to the main trial were included in this secondary analysis if the participating hospital laboratory used the same analysis methods on the routine day 1 samples as the central laboratory. This restriction of participants was necessary owing to marked bias seen between analysis methods (6 ).
LITERATURE REVIEW
A comprehensive search was made for all papers examining the effect of AMI on lipid concentrations in which the absolute concentration of cholesterol and triglycerides was given at specific time points and no lipid-modifying medication was administered during the study period. The search term "cholesterol acute changes after myocardial infarction" was used in PubMed, and subsequently all publications cited were explored. A comparative literature review was performed to enable a comparison of lipid changes reported in the published literature, in addition to those observed in the SPACE ROCKET trial.
STATISTICAL METHODS
SPACE ROCKET study. The Shapiro-Wilk test was used to test for normality; parametric and nonparametric tests were used to compare data for lipid concentrations obtained on day 1 with data on days 2-4. A Bonferroni-corrected P value of Ͻ0.025 was considered statistically significant. Analyses were performed using the Analyse-it (version 2.2) add-in package for Microsoft Excel (www.analyse-it.com).
Comparative literature review. Data on the mean cholesterol and triglyceride values at baseline and each reported time point were extracted from all identified studies. These data were used to calculate the percentage change from baseline. A formal metaanalysis based on the actual changes was not possible because of the lack of reporting of standard deviations. The mean percentage change across all studies was calculated as a weighted mean (weighting by sample size).
Results

SECONDARY ANALYSIS
A total of 1263 participants were enrolled into the SPACE ROCKET trial across 27 centers. Of these, 300 were enrolled at five hospitals using identical analytical methods for day 1 samples as the central laboratory. Lipid measurements were available on both day 1 and days 2-4 for 128 participants: 108 men (median age 59.0 years, range 40.7-88.1 years) and 20 women (65.5 years, 48.6 -85.4 years). Reasons for missing data included 38 missing day 1 samples and 1 missing day 2-4 samples and 133 samples taken Ͻ2 days or Ͼ4 days after admission. The lipid data for the entire cohort (n ϭ 1179; some data for day 1 were unavailable) for days 1 and 2-4 were total cholesterol 5.37 mmol/L (SD 1.27) and 4.53 mmol/L (1.04) and triglycerides 1.95 mmol/L (1.34) and 1.89 mmol/L (0.97), respectively. A total of 328 of 1263 (26%) participants were taking statins on admission to the trial. The subgroup of 128 participants included in this study had 20 individuals (15.6%) taking statins (14 taking simvastatin, 5 taking atorvastatin, and 1 taking pravastatin; 19 men, 1 woman). Five of the 32 who had LDL calculations at both time points were taking statins.
Lipid concentrations for the 128 SPACE ROCKET participants are shown in Table 1 . These individuals had all their lipid measurements made using Siemens Advia reagents and had their second sample taken during the day 2-4 window. A statistically significant difference was observed between the concentrations of total cholesterol obtained on days 2-4 compared with those obtained on day 1 (mean difference 0.71 mmol/L, 95% CI 0.58 -0.84; P Ͻ 0.0001). In contrast, no significant difference was observed between triglyceride concentrations on day 1 and days 2-4 (median difference of 0.02 mmol/L [95% CI Ϫ0.150 to ϩ0.200], Wilcoxon rank sum test, P ϭ 0.7341).
LITERATURE REVIEW
A total of 26 papers over the period of 1963-2008 were found showing concentrations of total cholesterol and triglycerides at identified days post-AMI; data from these studies are shown in Tables 2 and 3 . A total of 2122 study participants are described for cholesterol, and 1906 study participants are described for triglycerides. The median study size was 39 (range 12-565). The mean changes for total cholesterol and triglycerides were calculated, weighted according to the number of participants in each study. The combined data show that total cholesterol falls for the 14 days after ACS and takes 1-3 months to recover. In contrast, triglycerides rise by day 3 and remain increased for Ͼ3 months.
Discussion
Until recently, it has been widely accepted that serum cholesterol falls in the time immediately after AMI. This belief was based on studies ranging in size from 12 to 123 participants (see Table 2 ). The findings of the present study provide support for this argument, since we demonstrate a 0.55 mmol/L (10.6%) decrease in total cholesterol between days 1 and 2-4 after AMI.
However, this view has been challenged by Pitt et al. (3 ) , who recently published data from the LUNAR study, where lipid concentrations of 507 participants were recorded on days 1, 2, and 4 after ACS. In contrast to our findings, Pitt et al. reported a fall in serum total cholesterol of only 1.25% between days 1 and 2 and demonstrated an increase of 4.16% in total cholesterol between days 1 and 4. Although both these differences were statistically significant, the authors did not consider them to be clinically significant. Pitt et al. further stated that their findings did not differ significantly between groups based on the size of myocardial infarction, the delay in presentation, or whether the diagnosis was ACS or unstable angina.
In explanation of their findings, Pitt et al. (3 ) noted that the previously recognized fall in serum cholesterol was presumed to be an effect of the acute phase effect on lipoproteins (2 ). They proposed that their observation of lack of change in lipid variables may be explained by improvements made in patient management since the conduct of many of the previous studies investigating this issue (see Table 2 ). If true, this would result in a reduction in tissue damage and could be measured by inflammatory markers. Although Pitt et al. (3 ) did not measure any inflammatory markers, we found in a previous study of ACS management in West Yorkshire, England, during the period April to October 2003 (EMMACE-2), in 2499 study participants with confirmed ACS, the median C-reactive peptide was only 0.93 mg/L (range 0.02-48.2) (7, 8 ) . This finding indicates that The overall data (bottom row) shows the weighted mean as a percentage of the basal value.
even in that time period, the majority of study participants did not experience a severe inflammatory reaction. Moreover, over the 5 years since that study was performed, there have been further improvements in management of ACSs that might reduce the overall inflammatory burden. The findings do not, however, explain the difference in cholesterol changes between the LUNAR and SPACE ROCKET studies. It is not easy to reconcile these findings, since the study by Pitt et al. (3 ) represents 24% of all the published cases analyzed in this report, and almost all the other studies, as well as ours, demonstrate a fall in serum cholesterol of ϳ10% (see Table 2 ). The outcome of the Pitt et al. report is of clinical importance, since it may lead to a change in practice where blood is not sampled from patients within 24 h of ACS because there may be a belief that there is no urgency to do these tests. Importantly, Pitt et al. do advocate early testing. If, as we believe, there is a fall in cholesterol of 10% during this time after an ACS, then there is a risk that cholesterol is below a target and that important lipidlowering therapy will be withheld despite guidelines. Furthermore, there is evidence to suggest that lower lipid testing rates after ACS reduce the likelihood that patients will be treated with statins (9 ) , and recent audits show that women and the elderly are less likely to be given statins (10 ) .
Interestingly, the 3-month cholesterol value was greater than the baseline value in four of the six studies reviewed in this report (11, 16, 28, 34 ) . If the acute changes in lipids had returned to normal after 3 months, these data would suggest that the baseline post-AMI sample was in fact already lowered by the acute effect of the AMI and that the actual cholesterol lowering has been underestimated. Indeed, this delay in first sampling may explain the variability in the fall. Patients in the LUNAR study had their first sample taken after a median delay of 26 h. Pitt et al. (3 ) have studied the effect of the delay (over 5 days) on LDL cholesterol data and confirm the nadir at 24 h. In view of the insecurity of the time interval between the onset of an ACS and the time of blood sampling for lipid status, we propose that a baseline sample is taken as soon as possible and statins are commenced in a standard dose, but that the dose should not be tailored to the patient until 3 months after the acute event.
The science behind the design of diagnostic studies is emerging, and most of the studies reviewed in this report would not fulfill modern "evidence-based" requirements. However, the studies have been performed on patients who all had confirmed myocardial infarction using diagnostic criteria of the time, which would have meant the study participants had larger volumes of myocardial infarction than is the case with current diagnostic criteria. However, there would have been selection bias regarding inclusion and exclusion criteria. Unfortunately, the data published in many of these early studies were relatively incomplete, and therefore a formal metaanalysis based on the actual changes was not possible because of the lack of reporting of standard deviations. We have, however, attempted to determine whether there has been any publication bias affecting our findings with the aid of a funnel plot (see Fig. 1 ). We have used the maximum cholesterol fall, since there is considerable variation in sample time collection in the various studies. However, it should be noted again that the uncertainty in knowing the exact timing of the baseline value, as highlighted above, might be a fatal flaw in interpreting this technique for publication bias.
In conclusion, through analysis of SPACE ROCKET trial data and a comparison of previously published data, we report a 10% fall in total cholesterol after AMI-a difference that is of high clinical significance. These combined data challenge the findings of Pitt et al. (3 ) and suggest that further investigation is required to fully determine the extent of lipid changes after AMI and their underlying mechanisms. Sample size is used as a surrogate for standard error, since full data are not available for all studies.
